Vanderbilt University

FDA may approve KarXT, a novel antipsychotic for schizophrenia, potentially the first new treatment in 70 years. KarXT combines xanomeline and trospium to target brain receptors, reducing acute psychotic symptoms with fewer side effects. However, concerns include potential cardiovascular risks, unclear long-term efficacy, and high cost.

The article profiles various professionals in health and statistics, including John R. Lumpkin, M.D., M.P.H., Mollyann Brodie, Ph.D., Kennon R. Copeland, Ph.D., Tara Das, Ph.D., M.P.H., M.L.I.S., Scott H. Holan, Ph.D., V. Joseph Hotz, Ph.D., Bradley Malin, Ph.D., Sally C. Morton, Ph.D., Lucila Ohno-Machado, M.D., M.B.A., Ph.D., Andy Peytchev, Ph.D., C. Matthew Snipp, Ph.D., Kelly Hoover Thompson, J.D., and David R. Williams, Ph.D., detailing their roles, achievements, and contributions to their respective fields.

ZeroEyes' AI gun detection system implemented at Lane Dermatology, Sweden sees decline in melanoma among under-50s, study finds higher phthalate levels in young children using personal care products, Mary-Margaret Chren to retire from Vanderbilt and join Stanford, Medscape Education partners with Comprehensive Medical Mentoring Program to enhance dermatology diversity, NY Governor Kathy Hochul diagnosed with basal cell carcinoma.

Cancer patients with Duffy-null phenotype, common in African Americans, face exclusion from clinical trials due to naturally low neutrophil counts, highlighting racial bias in medical norms. A study in JAMA Network Open reveals 76.5% of trials and 53.5% of drug regimens unfairly exclude Duffy-null individuals, impacting treatment and survival.